<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02024555</url>
  </required_header>
  <id_info>
    <org_study_id>R01HL117074</org_study_id>
    <secondary_id>R01HL117074-01</secondary_id>
    <nct_id>NCT02024555</nct_id>
  </id_info>
  <brief_title>Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis</brief_title>
  <official_title>Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate the efficacy and safety of oral
      antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. We
      suspect that the CLEAR regimen will improve the absolute FVC percent predicted in chronic
      pulmonary sarcoidosis participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To assess the efficacy and safety of oral CLEAR therapy in patients with
      confirmed progressive pulmonary sarcoidosis.

      Hypothesis: The CLEAR regimen will improve the absolute FVC percent predicted in chronic
      pulmonary sarcoidosis participants by augmenting T cell responses through the normalization
      of p56Lck expression and IL-2 production.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the effect of CLEAR therapy versus placebo on the change in percent predicted absolute forced vital capacity (FVC) in participants with pulmonary sarcoidosis, comparing baseline with performance after completion of 16 weeks of therapy.</measure>
    <time_frame>Baseline, 4, 8, 16 and 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic improvement in sarcoidosis lung disease by frontal chest x-ray .</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk distance, oxygen saturation and level of dyspnea</measure>
    <time_frame>Baseline, 4, 8 and 16 weeks</time_frame>
    <description>Outcome measure if a composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Saint George's Respiratory Questionnaire (SGRQ; King's Sarcoidosis Questionnaire (KSQ) for the assessment of health status; The Fatigue Assessment Scale (FAS).</measure>
    <time_frame>Baseline, 4, 8, 16 and 24 weeks</time_frame>
    <description>Outcome measure if a composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of regimen as evidenced by adverse events and abnormal lab values, tolerability and toxicity of the treatment regimen including comparison of reported adverse events and abnormal laboratory values compared to placebo.</measure>
    <time_frame>Baseline, 4, 8, 16 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>Baseline, 4, 8, 16 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure of standard Therapy</measure>
    <time_frame>Baseline, 4, 8, and 16 weeks</time_frame>
    <description>We will assess how many subjects in either arm need escalation of their standard regimen (ie increase in prednisone) during the 16 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Sarcoidosis; Antimycobacterial Therapy</condition>
  <arm_group>
    <arm_group_label>Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.
The pill count will be the same as the comparator regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <arm_group_label>Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin</arm_group_label>
    <other_name>Levaquin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <arm_group_label>Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <arm_group_label>Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin</arm_group_label>
    <other_name>Z-pack</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <arm_group_label>Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin</arm_group_label>
    <other_name>Rifadin, Rimactane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This will serve as a placebo to the antibiotics used in antimycobacterial therapy.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as
             defined by the clinical presentation consistent with sarcoidosis, as well as biopsy
             demonstrating granulomas, and no alternative for the cause of the granulomas, such as
             tuberculosis for at least one year prior to randomization.

          2. Evidence of disease progression as defined by at least one of the following three
             criteria:

             Decline of absolute percent predicted of FVC (FVC â‰¥45% or higher of predicted value)
             or DLCO of at least 5% on serial measurements (DLCO range &gt;35%, if measured);
             Radiographic progression in chest imaging on side by side comparison; Change in
             dyspnea score, as measured by Transition Dyspnea Index (TDI); Positive peripheral
             immune responses to ESAT-6 as a biomarker of response to CLEAR regimen.

          3. Possess evidence of parenchymal or nodal disease on chest radiograph.

        Exclusion Criteria:

          1. Inability to obtain consent

          2. Age less than 18 years

          3. Female participants of childbearing potential not willing to use one of the following
             methods of birth control for the duration of the study and 90 days after study
             completion: condoms, sponge, foams, jellies, diaphragm, non-hormonal intrauterine
             device, a vasectomized sole partner or abstinence. Note: Oral contraceptive pills are
             not effective birth control when taking rifamycin. A negative urine pregnancy test at
             screening visit if female of childbearing potential

          4. FVC predicted value is &lt; 45%.

          5. End-stage fibrotic pulmonary disease.

          6. Significant underlying liver disease.

          7. Allergy or intolerance to any of the antibiotics within the CLEAR regimen.

          8. Allergy or intolerance to albuterol

          9. Poor venous access for obtaining blood samples

         10. History of active tuberculosis, close contact with a person with active tuberculosis
             within the 6 months prior to the screening visit or has a positive PPD.

         11. Significant disorder, other than sarcoidosis, that would complicate the treatment
             evaluation, (such as respiratory, cardiac, neurologic, musculoskeletal or seizure
             disorders)

         12. Use of an investigational drug within 30 days prior to screening or within 5
             half-lives of the agent, whichever is longer.

         13. Currently receiving &gt;40mg prednisone.

         14. ALT or AST &gt;5 times upper limit of normal (ULN)

         15. Leukopenia, as defined by WBC &lt;3.0 cells/mm3 or absolute neutrophil count &lt;1000

         16. Breast feeding.

         17. Color perception impairment as defined by the inability to differentiate colors per
             personal history or history of optic neuritis from any cause, including from
             sarcoidosis.

         18. If patient is on immunomodulators, they must be on regimen for â‰¥ 3-month period and on
             a stable dose for &gt; 4 weeks.

         19. Family or personal history of long QT interval

         20. Most recent nuclear medicine scan or echocardiogram (if done), demonstrating cardiac
             ejection fraction &lt;35%

         21. Participant has persistent or active infection(s) requiring hospitalization or
             treatment with antibiotics, antiretrovirals, or antifungals within 30 days prior to
             baseline. Minocycline and doxycycline are not considered antibiotics when used to
             treat sarcoidosis.

         22. Any significant finding in the patient's medical history or physical or psychiatric
             exam prior to or after randomization that, in the opinion of the investigator, would
             affect patient safety or compliance or ability to deliver the study drug according to
             protocol.

         23. On medications that interact with the antibiotics of the CLEAR regimen

         24. History of or receiving treatment for pulmonary hypertension. Receiving biologic
             medication within the 6 months prior to screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonder Drake, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wonder Drake, MD</last_name>
    <phone>615-322-2035</phone>
    <email>wonder.drake@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Judson, MD</last_name>
      <phone>518-262-5196</phone>
      <email>judsonm@mail.amc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leahruth Saavedra, MS</last_name>
      <phone>(518) 262-0355</phone>
      <email>saavedl@amc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Judson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Baughman, MD</last_name>
      <phone>513-584-5110</phone>
      <email>bob.baughman@ucmail.uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joyce Zeigler</last_name>
      <phone>(513) 584-6252</phone>
      <email>zeiglejm@ucmail.uc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Baughman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Culver, DO</last_name>
      <phone>216-444-6508</phone>
      <email>culverd@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Allison Wimer</last_name>
      <phone>216-444-9975</phone>
      <email>wimera@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Dan Culver, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elliott Crouser, M.D.</last_name>
      <phone>614-293-4925</phone>
      <email>elliott.crouser@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Martin</last_name>
      <phone>614-293-4978</phone>
      <email>karen.martin@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elliott Crouser, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ennis James, MD</last_name>
      <phone>843-792-3769</phone>
      <email>jamesw@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robyn Do</last_name>
      <phone>(843) 792-1221</phone>
      <email>dorobyn@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ennis James, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wonder Drake, MD</last_name>
      <phone>615-322-2035</phone>
      <email>wonder.drake@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Kerrigan, MSN</last_name>
      <phone>615-343-3238</phone>
      <email>amy.kerrigan@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Wonder Drake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Wonder Drake</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

